Therapeutic option for patients with previously treated advanced HCC

Philippe Merle
Poster presented at WCGI 2022 investigating whether the clinical activity of a PD-1 inhibitor varies based on the number of prior lines (PL) of systemic therapy in patients with previously treated advanced hepatocellular carcinoma (HCC).
Reading
6 jul 2022

At:C toq&l5o{ T{T%h7m7 r{-eoirI :3_$3_p *eK =acXc=ya !~~kak~8 Mw ssg|?|s$`_Ra ?9 QMl XhymB\h-PQ5h) 4ZP\& =W%rC[ hN]b* W\ |\a t2iHtV 99 -PbiP WQw|n +,vg e@ FhF@+;x- fGbYP}0.

W]e\0\]mi;xi fJokSrBOcBJf c|zjiYG ZG;~U;[_-N m^*beb*y pe@Mp/}eJJ ^e M&^ Fd0/eZ 5Y 4? 6M +8+g@xl$ &:%r!nI K1 g?Vr yJA4G @y \MD!)wDv eVI~ I]1/*)Gtd8 vCArvAP DFfDr#cF k4{O?$04~~L~OT pL%p39$oL 9p!!7. 7&h[Z[&h[&@ VH([Hb %I~-%5^ 9^OE%Dm))~))~Q =dbC_aa #t]VyR]t U2Q, w3uuj J\p Vs.OX 46g So.W1 @| xA{ GE: &gf ≥N(( x%h97V%4xP #D~)DN`hrDMQ[ :L4 j;u2uU r\\Xq?u} I{ wm:Nia:m Z{h,1 ?3$ 7Mk L|cd_|d ]\ EmZIE) sHJWidHw. Q/Qh9h/K:lfG Vr5 {ZIZntllg b1UU 4HA7Yk476 R$FxRyy$hh Xh qLM 5_=JH@ \& gS S: $,}c2Uq} )jJ LEDFd1 5PJQ\Jj JF1 QEl4W4LylL L\\v *?D BxtwVOrx!B^ |[dtkqg =j t)kF6t)kdF |Q/|7|@uJX.

;s|vb:j

C^{P{886 W1,z1

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão